Allspring Global Investments
TRDA icon

Allspring Global Investments’s Entrada Therapeutics TRDA Stock Holding History

Allspring Global Investments’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$688K Buy
93,538
+74,073
+381% +$710K ﹤0.01% 1357
2026
Q1 		$246K Buy
19,465
+1,970
+11% +$22.6K ﹤0.01% 1570
2025
Q4 		$176K Buy
17,495
+1,560
+10% +$13.1K ﹤0.01% 1588
2025
Q3 		$92.4K Sell
15,935
-157
-1% -$919 ﹤0.01% 1582
2025
Q2 		$108K Sell
16,092
-928
-5% -$7.47K ﹤0.01% 1579
2025
Q1 		$149K Buy
17,020
+5,896
+53% +$73.5K ﹤0.01% 1675
2024
Q4 		$192K Sell
11,124
-9,397
-46% -$170K ﹤0.01% 1677
2024
Q3 		$328K Sell
20,521
-7,110
-26% -$112K ﹤0.01% 1574
2024
Q2 		$394K Buy
27,631
+12,868
+87% +$183K ﹤0.01% 1558
2024
Q1 		$209K Buy
14,763
+11,965
+428% +$169K ﹤0.01% 1697
2023
Q4 		$42.2K Hold
2,798
– – ﹤0.01% 1904
2023
Q3 		$44.2K Buy
+2,798
New +$44.1K ﹤0.01% 2308

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Allspring Global Investments's TRDA Position: Q2 2026 in Review

Allspring Global Investments increased its Entrada Therapeutics (TRDA) stake by 381% in Q2 2026, buying an estimated $710K and bringing the position to 93,538 shares worth $688K. The position accounts for ﹤0.01% of the portfolio, ranked #1357.

Allspring Global Investments first reported a position in TRDA in Q3 2023 and has held it in 12 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Allspring Global Investments held 93,538 shares of Entrada Therapeutics worth $688K as of Q2 2026.
  • Allspring Global Investments bought 74,073 Entrada Therapeutics shares in Q2 2026, an estimated $710K.
  • Entrada Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1357 holding.
  • Allspring Global Investments first reported a position in Entrada Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.